Accreditation

This educational activity is specifically designed for hematologists, hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

After completing this activity, participants should be able to:

• Describe the role of emerging therapies in improving outcomes based on data from recent clinical studies
• Interpret safety-efficacy profiles of current and emerging pharmacologic agents
• Assess the role of sequencing and combination therapies
• Devise the best treatment approach for transplant-eligible and transplant-ineligible patients
• Evaluate the emerging role of immunotherapies
• Assess the role of chemotherapy either alone or in combination with novel agents
• Evaluate the role of new and existing biomarkers
• Describe how the biology and/or pathogenesis informs precision medicine
• Debate the benefits and risks of novel diagnostic and prognostic approaches

HMP Education designates this live activity for a maximum 27.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This live, knowledge-based activity (UAN: JA0006201-0000-23-118-L01-P) has been approved for a maximum of 27.75 contact hours (2.8 CEUs).

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

This continuing nursing education activity awards 27.75 contact hour(s). Provider approved by the California Board of Registered Nursing, Provider #13255 for 27.75 contact hour(s).

HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This live activity is designated for 27.75 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Joy, Senior Manager, Accreditation and Compliance, by phone at 609.371.1137, by email at accreditation@hmpglobal.com, or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Joy will review the grievance and respond within 30 days of receiving the complaint.

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609.371.1137.

This meeting is supported by educational grants from AstraZeneca Pharmaceuticals, BeiGene Inc, USA, Incyte, Janssen Biotech Inc, administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Novartis Pharmaceutical Corporation, Pharmacyclics, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs, LLC

Copyright © 2023 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.